evipedia.ai
← Back

DSIP for Health & Longevity

Evidence Review created on 09/30/2026 using AI4L / Opus 5.5

Also known as: Delta Sleep-Inducing Peptide, Delta-Sleep-Inducing Peptide, δ-Sleep-Inducing Peptide, Emideltide, Emideltide Acetate, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, WAGGDASGE

Motivation

DSIP (delta sleep-inducing peptide) is a short chain of nine amino acids that Swiss researchers found in the blood of rabbits during artificially induced deep sleep. Today it is sold as an injectable research peptide and promoted in longevity circles for deeper sleep, better stress resilience and slower aging. Its main proposed action is to nudge the brain toward the slow, deep phase of sleep, although no dedicated docking site for it on brain cells has ever been found.

Interest peaked in the late 1970s and 1980s, when small human studies tested the peptide mainly for chronic insomnia. Russian laboratories later tested a preparation containing it in aging animals. In 2026 a United States federal advisory panel reviewed whether pharmacies may prepare it, which renewed public attention.

This review examines what the human and animal evidence shows about DSIP for sleep, stress and healthy aging, which risks come with self-injecting an unapproved peptide, and how current use and product quality compare with the conditions under which it was originally studied.

Benefits - Risks - Protocol - Conclusion

This section lists in-depth reviews, primary studies and expert commentary that give a high-level overview of DSIP.

None of the six prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on DSIP: web searches and on-site searches of each platform returned no relevant results, most likely because DSIP is an unapproved research peptide with a thin, decades-old human evidence base.

Grokipedia

  • Delta-sleep-inducing peptide

    An AI-generated encyclopedia entry summarizing DSIP’s discovery, structure, proposed mechanisms, early clinical studies and recent animal work; useful for orientation, though it is a secondary summary rather than a primary source.

Examine

No Examine article on DSIP exists. Examine.com does not cover DSIP, which is an unapproved injectable research peptide rather than a dietary supplement.

ConsumerLab

No ConsumerLab article on DSIP exists. ConsumerLab tests dietary supplements, and DSIP is sold only as an unapproved injectable research peptide; the site’s peptide coverage centers on BPC-157 and TB-500.

Systematic Reviews

No systematic reviews or meta-analyses for DSIP were found on PubMed as of 2026-09-30.

Mechanism of Action

DSIP is a nonapeptide (a chain of nine amino acids: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) with no identified gene, precursor protein or dedicated receptor, so its mechanism remains a set of hypotheses (Kovalzon & Strekalova, 2006).

  • Sleep rhythms: Infused into rabbit brain ventricles (fluid spaces), DSIP increased slow delta waves and sleep spindles (brief brain-wave bursts of light sleep) on the EEG (electroencephalogram, a recording of brain electrical activity) (Schoenenberger & Monnier, 1977). Dose responses are bell-shaped: higher doses often work less well.
  • Neurotransmitter and stress systems: Animal work points to modulation of NMDA receptors (N-methyl-D-aspartate receptors, the main excitatory glutamate receptors) and opioid-like actions that naloxone (an opioid-blocking drug) reverses.
  • Mitochondria and antioxidants: Rat studies, largely co-authored by the Moscow institute that developed the DSIP product Deltaran, report more efficient cellular energy production under low oxygen (Khvatova et al., 2003).
  • Pharmacology: Blood peptidases (protein-cutting enzymes) cleave tryptophan from DSIP within minutes, giving a plasma half-life of minutes (Graf et al., 1987). No CYP (cytochrome P450, the main liver drug-metabolizing enzymes) involvement is known. A saturable carrier (a transport protein with limited capacity) moves it into the brain (Zlokovic et al., 1989); DSIP-like material occurs in the hypothalamus (the brain’s hormone-control region), pituitary gland, other organs and plasma. Oral use is impractical: intestinal cells degrade it (Augustijns & Borchardt, 1995).
  • Competing views: Critics argue the native peptide is too unstable to be a physiological sleep signal; supporters cite effects lasting hours after single injections, suggesting a trigger-like action.

Historical Context & Evolution

DSIP was isolated in 1977 by Guido Schoenenberger and Marcel Monnier in Basel from the blood of rabbits whose thalamus (a deep brain relay center) was electrically stimulated to induce sleep (Schoenenberger & Monnier, 1977). Its original intended use was as a natural sleep factor and a candidate treatment for insomnia.

During the 1980s the Basel group, with psychiatrist Dieter Schneider-Helmert, reported that intravenous DSIP normalized sleep in chronic insomnia and improved daytime performance (Schneider-Helmert, 1987). Geneva researchers, whose senior author co-invented a Hoffmann-La Roche withdrawal patent, reported rapid relief of alcohol and opioid withdrawal (Dick et al., 1984). Independent placebo-controlled trials in Uruguay (Monti et al., 1987) and Amsterdam (Bes et al., 1992) found only small effects of little clinical significance. Kastin’s group warned that the “sleep-inducing” label oversimplified a peptide with many actions (Kastin et al., 1983), and no gene was found. Development stopped, although neither side’s data were refuted: trials differed in dosing, patients and outcomes.

From the 1990s, Russian groups developed the preparation Deltaran and reported stress-protective and lifespan effects in animals, bringing DSIP into health-optimization and peptide-therapy circles. The US Food and Drug Administration (FDA) listed DSIP among compounding substances raising safety concerns in 2023, removed it in April 2026, and its advisory committee narrowly voted against pharmacy compounding in July 2026.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the controlled human data are three small placebo-controlled insomnia trials with conflicting results and small hormone studies with mixed results, and no clinical outcome has been replicated across independent trials.

Medium 🟩 🟩

No benefit reaches Medium: no clinical outcome rests on a single controlled human trial left uncontradicted, and all other human data come from uncontrolled case series or pre–post comparisons.

Low 🟩

Better Sleep in Chronic Insomnia ⚠️ Conflicted

DSIP was tested for faster, more efficient sleep in insomnia. The Basel group’s double-blind trial in 14 patients reported normal-range sleep efficiency (share of time in bed spent asleep) (Schneider-Helmert, 1987). Independent randomized trials found weak changes (Bes et al., 1992). Net: any benefit appears modest and unconfirmed independently.

Magnitude: Direction favored DSIP for sleep efficiency and sleep latency (time to fall asleep) after 3–7 daily intravenous doses of 25–30 nmol/kg, but the trial reports give no outcome figures in their abstracts, and the independent Amsterdam and Uruguay trials judged the differences clinically insignificant (Monti et al., 1987).

Daytime Alertness and Performance

Insomniacs showed higher daytime alertness and mental performance after six injections (Schneider-Helmert, 1987). A single narcolepsy (sudden daytime sleep attacks) case improved similarly (Schneider-Helmert, 1984). Both used pre–post comparisons from one research team.

Magnitude: Not quantified in available studies. The reports describe statistically significant pre–post improvements without effect sizes, and no independent study measured daytime function.

Relief of Alcohol and Opioid Withdrawal ⭕️ Not Central to Health & Longevity

Open series of 107 inpatients reported rapid withdrawal relief (Dick et al., 1984); senior author René Tissot co-invented the Hoffmann-La Roche withdrawal patent. There was no placebo group. This bears on addiction treatment, not healthy aging.

Magnitude: Symptoms disappeared or improved markedly in 97% of evaluable opioid and 87% of evaluable alcohol withdrawal patients, in an uncontrolled series that excluded 13–22% of patients from evaluation.

Chronic Pain and Headache Relief

A pilot study gave intravenous DSIP to seven patients with migraine, blood-vessel-related headache, tinnitus (ringing in the ears) or pain of psychological origin (Larbig et al., 1984). Co-occurring depressive symptoms also eased. There was no control group.

Magnitude: Pain levels fell significantly in 6 of 7 patients versus their own baseline after 10 injections given over about three weeks.

Glucose and Well-Being in Older Adults with Diabetes

An uncontrolled pilot gave 20 daily doses of Deltaran to 11 older diabetics (mean age 66). Post-meal glucose, memory, mood and anxiety scores improved (Odin et al., 2004). Placebo effects and regression to the mean (natural drift of extreme values back toward normal) cannot be excluded.

Magnitude: Post-meal glucose and anxiety and memory scores moved favorably after 60 days in 11 patients; the report gives statistical significance but no outcome figures.

Stress Resilience

In double-blind Basel studies, psychological tests and psychotherapist ratings suggested better stress tolerance and coping after DSIP (Schneider-Helmert & Schoenenberger, 1983). In rats, DSIP damped stress-induced activation of the hypothalamic stress center (Umriukhin et al., 2012). No validated human stress outcome was measured.

Magnitude: Not quantified in available studies. The human report gives only qualitative psychotherapist ratings, and no controlled trial measured a validated stress or resilience scale.

Speculative 🟨

Hormonal Modulation ⚠️ Conflicted

Randomized trials found a drop in ACTH (pituitary signal for cortisol) (Bjartell et al., 1989), but stimulated ACTH, cortisol (Späth-Schwalbe et al., 1995) and growth hormone were unchanged. Net: a biomarker shift without downstream benefit.

Longer Maximum Lifespan

Lifelong monthly Deltaran courses in female mice left mean lifespan unchanged but extended maximum lifespan by 24.1% (Popovich et al., 2003). The basis is animal data only.

Fewer Spontaneous Tumors

The same mice had 2.6-fold fewer spontaneous tumors, mainly breast cancers and leukemias, and 22.6% fewer bone-marrow chromosome aberrations (Popovich et al., 2003). The basis is one mouse strain from one research network.

Antioxidant and Mitochondrial Protection

Monthly DSIP courses in aging rats raised antioxidant enzyme gene expression (Kutilin et al., 2014, co-authored by Deltaran’s developers) and reduced protein oxidation. The basis is animal biomarker data only.

Faster Recovery After Stroke

Intranasal DSIP for eight days accelerated motor recovery after experimental stroke in rats, without significantly smaller infarcts (dead-tissue areas) (Tukhovskaya et al., 2021, from Deltaran’s developing institute). The basis is one animal study.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. Because blood peptidases rather than liver CYP enzymes break DSIP down, common drug-metabolism gene variants are not expected to alter its effect.
  • Baseline sleep severity: In insomniacs aged 29–83, the size of the sleep improvement correlated with the degree of baseline sleep disturbance; people with near-normal sleep have little room to improve (Schneider-Helmert, 1986).
  • Baseline biomarkers: Plasma DSIP-like levels did not differ between healthy people and patients with sleep apnea (repeated breathing pauses during sleep) or narcolepsy, so no blood test predicts response (Vgontzas et al., 1995).
  • Sex: No sex-specific efficacy data exist; insomnia trials pooled men and women, and the hormone studies each used a single sex.
  • Age: Insomniacs aged 60–83 showed a larger immediate response than middle-aged patients but reached normal sleep only after an extra follow-up week (Schneider-Helmert, 1986).
  • Pre-existing conditions: Benefit is least plausible where poor sleep stems from untreated sleep apnea, depression or pain; long-standing sleep-medication dependence limited response in an open study (Kaeser, 1984).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from small trials and case series, mostly from the 1980s–1990s, totaling a few hundred treated people, none designed to detect uncommon harms.

Medium 🟥 🟥

Unintended Daytime Sleepiness

DSIP can create sleep pressure outside the intended window. In a double-blind crossover study (each person received both treatments) of six healthy volunteers, a morning intravenous infusion increased sleep over the following two hours, although testing found no classic drug sedation (Schneider-Helmert et al., 1981). Basel studies reported sleep-promoting effects lasting up to 20 hours (Schneider-Helmert & Schoenenberger, 1983). This matters for driving and machine operation.

Magnitude: Median total sleep time rose 59% versus placebo within 130 minutes after a 25 nmol/kg morning infusion.

Low 🟥

Headache

Headache was the only adverse event noted in the largest human series of 107 withdrawal patients, reported by “a few” patients (Dick et al., 1984). Without a placebo group, attribution to DSIP is uncertain.

Magnitude: Not quantified in available studies. The series reported headache in “a few” patients without counts, and no controlled trial tabulated adverse events.

Faster Heart Rate and Reduced Heart Rate Variability

In a randomized study of 24 women undergoing surgery, intravenous DSIP raised heart rate and lowered heart rate variability (beat-to-beat timing variation, a marker of calming nervous-system tone), suggesting reduced parasympathetic (rest-and-digest) activity (Pomfrett et al., 2009). Findings came during anesthesia, so relevance to bedtime use is uncertain.

Magnitude: Heart rate rose and heart rate variability fell after single intravenous doses of 25–100 nmol/kg in 12 women; the report gives statistical significance but no outcome figures.

Speculative 🟨

Impurities, Contamination and Immune Reactions

FDA reviewers cited poor characterization and possible synthesis impurities such as truncated peptides (Eglovitch, 2026). Non-sterile products add infection and immune-reaction risk. The basis is manufacturing concern, not reported cases.

Harm During Acute Heart or Brain Ischemia

In a rat ischemia (blocked blood flow) pilot by Deltaran’s developers, DSIP given during coronary blockage caused 100% mortality (Tukhovskaya et al., 2021); an analogue did likewise in stroke. The basis is animal data only.

Unknown Long-Term Effects

No human was followed beyond weeks of dosing, so chronic hormonal or immune effects are unstudied. Lifelong mouse dosing reduced body weight without reported toxicity (Popovich et al., 2003). The basis is absence of data.

Risk-Modifying Factors

  • Genetic polymorphisms: No genetic variants are known to alter DSIP’s safety; its breakdown by blood peptidases makes common liver-enzyme variants unlikely to matter.
  • Baseline biomarkers: No biomarker predicts adverse effects. Baseline liver and kidney values help separate pre-existing abnormalities from any change after using an unregulated injectable.
  • Sex: No sex-specific adverse-event data exist. Women who are pregnant, planning pregnancy or breastfeeding have no safety data at all.
  • Pre-existing conditions: Untreated sleep apnea, recent heart attack or stroke (given the animal ischemia signal), and active alcohol or opioid dependence raise risk; alcohol withdrawal can cause seizures that DSIP does not prevent.
  • Age: Older adults are more vulnerable to next-day drowsiness and falls, especially when DSIP is combined with other sleep-promoting drugs; no age-specific safety data exist.

Key Interactions & Contraindications

  • Prescription sleep medications (zolpidem, eszopiclone, temazepam, lorazepam): Caution. Additive sleepiness and impaired next-day function are plausible but unstudied. Mitigation: avoiding same-night combination, or lowest doses and no driving the next morning.
  • Opioids (oxycodone, morphine, methadone, buprenorphine): Caution. DSIP’s opioid-like animal actions may add to sedation. Mitigation: no unsupervised use during opioid therapy or tapering; prescriber coordination.
  • Opioid antagonists (drugs that block opioid receptors: naltrexone, naloxone): Monitor. Animal data suggest they may block some DSIP effects, reducing benefit; no dangerous reaction is expected.
  • Other sedating prescription drugs (gabapentin, pregabalin, trazodone, mirtazapine, quetiapine): Caution. Additive drowsiness and fall risk. Mitigation: adding DSIP only to a stable regimen and checking morning alertness for one week.
  • Over-the-counter sleep aids and sedating antihistamines (allergy drugs causing drowsiness: diphenhydramine, doxylamine): Caution. Additive drowsiness and next-day impairment. Mitigation: no same-night combination.
  • Alcohol: Caution. Additive sedation, and DSIP modulates ethanol effects in animals. Mitigation: no alcohol within about 6 hours of a dose.
  • Supplements with additive sleep effects (melatonin, magnesium glycinate, glycine, valerian, kava): Monitor. Additive drowsiness; kava also carries liver risk. Mitigation: adding one agent at a time and reassessing morning alertness.
  • L-tryptophan supplements: Monitor. Tryptophan inhibited DSIP’s carrier-mediated brain uptake in guinea pigs, possibly reducing effect (Zlokovic et al., 1989). Mitigation: separating doses by several hours.
  • Other interventions (cognitive behavioral therapy for insomnia, continuous positive airway pressure): No negative interaction is known; both are compatible with DSIP, which does not replace apnea treatment.

Populations who should avoid DSIP:

  • Pregnant or breastfeeding women (any trimester)
  • People under 18 years of age
  • Untreated moderate-to-severe obstructive sleep apnea (apnea–hypopnea index, the number of breathing pauses per hour, ≥15 events/hour)
  • Heart attack, unstable angina (chest pain at rest or rapidly worsening) or stroke within the past 90 days
  • Active alcohol or opioid withdrawal outside medical supervision
  • Competitive athletes under World Anti-Doping Agency testing (unapproved substances fall under prohibited class S0)
  • Known allergy to DSIP or any other product ingredient

Risk Mitigation Strategies

  • Verified product: Material with an independent certificate showing ≥98% purity by HPLC (high-performance liquid chromatography, a purity test), mass-spectrometry identity near 849 daltons, and bacterial-toxin and sterility testing mitigates impurity and contamination risk.
  • Evening dosing only: Dosing 1–3 hours before bed, never in the morning or before driving, limits unintended daytime sleepiness.
  • No driving after first doses: Refraining from driving or operating machinery for 24 hours after the first two doses mitigates accident risk, since effects lasted up to 20 hours in trials.
  • No sedative stacking: Keeping alcohol, sleep medications and sedating antihistamines off dosing nights prevents additive sleepiness and falls.
  • Sterile technique: Reconstitution with bacteriostatic water, single-use insulin syringes, alcohol swabs, refrigeration at 2–8 °C and discarding solutions within 4 weeks prevent injection-site infection.
  • Slow, low start: Clinic protocols start at the low end (100 µg subcutaneously) with slow injection, which the Basel group found essential (Schneider-Helmert & Schoenenberger, 1983); this limits headache and reactions.
  • Sleep apnea screening first: A STOP-BANG questionnaire (an 8-item apnea risk screen) or home sleep test before use prevents masked or worsened apnea.
  • Short courses: Courses of 1–2 weeks with equal breaks limit exposure, given unknown long-term effects.
  • Stopping during acute cardiovascular events: Immediate discontinuation and emergency care with chest pain or stroke symptoms address the animal ischemia signal.

Therapeutic Protocol

  • Basel clinical protocol (Schneider-Helmert, Schoenenberger): 25–30 nmol/kg (about 20–25 µg/kg, roughly 1.5 mg for 70 kg) by slow intravenous injection, usually in the evening, for 4–7 consecutive days; used in all controlled insomnia trials.
  • Russian course protocol (Anisimov, Mikhaleva): Deltaran (DSIP plus glycine, 0.3 mg DSIP per intranasal ampoule) was used in 20-dose human courses; animal longevity studies injected DSIP on 5 consecutive days monthly. Human-equivalent dosing remains unvalidated.
  • Peptide-clinic protocol: Clinic and vendor materials commonly cite 100–300 µg subcutaneously 1–3 hours before bed in short cycles; peptide-therapy practitioners group DSIP among “recovery” peptides (Rahman et al., 2026).
  • Intranasal route: Tested experimentally in humans for an attention-related brain-wave response (Hruz et al., 2001) and in rats after stroke; no human sleep-outcome trial exists.
  • Conventional alternatives: Cognitive behavioral therapy for insomnia and approved sleep medications have far larger evidence bases; DSIP is used by some as an add-on or alternative when these fail or are unwanted.
  • Time of day: Evening dosing is standard. Morning injections still improved the following night’s sleep, but twice-daily dosing lost the benefit (Schneider-Helmert, 1984).
  • Half-life: Plasma half-life is only minutes, yet effects lasted hours and built up over about four consecutive doses, suggesting a trigger-like action rather than one requiring sustained blood levels.
  • Single versus split dose: A single daily dose is standard; split twice-daily dosing reduced effectiveness in the Basel studies.
  • Genetic polymorphisms: No genetic variants are known to guide DSIP dosing; weight-based dosing was used in trials.
  • Sex: No sex-based dosing differences have been studied; trials dosed men and women identically per kilogram of body weight.
  • Age: Adults up to 83 received standard weight-based doses; older adults may need 1–2 weeks longer to reach full effect.
  • Baseline biomarkers: Baseline sleep efficiency and severity scores set expectations, because response scaled with baseline disturbance.
  • Pre-existing conditions: Where sleep apnea, depression, pain or substance use drives insomnia, DSIP does not address the cause; it was studied mainly in primary (psychophysiological, driven by learned tension and worry about sleep) insomnia.

Discontinuation & Cycling

  • Short-term by design: All human protocols lasted 1–4 weeks; an open study reported normal sleep persisting 3–7 months after a 10-injection series (Kaeser, 1984). No evidence supports lifelong use.
  • Withdrawal effects: None were reported; sleep improvements persisted on the first placebo night after treatment, with no rebound insomnia.
  • Tapering: Not required; trials stopped abruptly without adverse effects.
  • Cycling: Monthly 5-day Russian courses and clinic “on/off” schedules are conventions; bell-shaped dose responses and weaker effects with twice-daily dosing argue against continuous high exposure, but no study tested cycling for maintaining efficacy.

Sourcing and Quality

  • Regulatory status of supply: No FDA-approved DSIP product exists. It is sold as “research use only” lyophilized (freeze-dried) powder, typically in 2–5 mg vials, and is not a legal dietary supplement.
  • Compounding: FDA removed DSIP from its “significant safety concerns” list in April 2026 (González-Rivera & Lee, 2026), but its advisory committee voted 6–7 against compounding use; no clear US pharmacy pathway exists as of September 2026.
  • Purity testing: Quality markers include independent third-party HPLC purity ≥98%, mass-spectrometry identity, stated net peptide content (acetate salt adds weight), bacterial-toxin and sterility results, and batch numbers matching the vial.
  • Formulation and storage: DSIP degrades rapidly in solution; powder is stored frozen or refrigerated and reconstituted with bacteriostatic water. Oral and sublingual products are of doubtful value because digestive enzymes destroy the peptide.
  • Reputable manufacturers: Research-grade DSIP from established peptide manufacturers such as Bachem is sold for laboratory use only; no brand offers a verified human-grade product in the US, and the Russian Deltaran preparation is not approved in the West.

Practical Considerations

  • Time to effect: Sleep pressure appeared about 1 hour after intravenous injection; insomnia normalized after about four consecutive doses, and older adults needed up to two weeks including follow-up.
  • Common pitfalls: Expecting a strong sedative effect, raising doses despite bell-shaped responses, twice-daily dosing, stacking sedatives, buying oral products, and trusting vendor-issued purity certificates.
  • Regulatory status: DSIP is not approved as a drug in the US or EU; FDA advisors voted against compounding in July 2026, and the World Anti-Doping Agency prohibits unapproved substances.
  • Evidence age: The last controlled human sleep trial was published in 1992 and the last controlled human study of any kind in 2009; modern subcutaneous peptide-clinic protocols have never been tested in trials.
  • Cost and accessibility: Gray-market vials are inexpensive, but legal access to a verified pharmaceutical-grade product is effectively unavailable in the US.

Interaction with Foundational Habits

  • Sleep: Direct, potentiating. DSIP targets deep sleep, but all trials ran in sleep laboratories with fixed schedules. Consistent bed and wake times, a dark cool room, and cognitive behavioral therapy for insomnia address causes DSIP does not.
  • Nutrition: Indirect. Rat studies report lower glycated hemoglobin and blood lipids with DSIP. L-tryptophan inhibited DSIP brain uptake in guinea pigs, so high-dose tryptophan supplements are best separated from dosing; evening alcohol adds sedation.
  • Exercise: None established. Claims of growth-hormone release are not supported: DSIP did not change growth hormone in healthy women (Giusti et al., 1993). Regular exercise itself deepens slow-wave sleep; no dosing adjustment around workouts has been studied.
  • Stress management: Indirect, possibly potentiating. Rat studies show damped hypothalamic stress activation, but DSIP did not alter cortisol responses in healthy men. Meditation, breathing practices and daylight exposure remain the evidence-based stress tools.

Monitoring Protocol & Defining Success

Before starting, a baseline assessment establishes current sleep, excludes sleep apnea, and documents metabolic, liver and kidney status, since DSIP is an unregulated injectable whose effects on glucose and hormones are unsettled. At least one week of sleep-diary or wearable data provides a personal reference, and a validated insomnia questionnaire quantifies severity.

Ongoing monitoring follows at 1 week and 2 weeks into each course (sleep questionnaire, diary or wearable, morning alertness), then every 3–6 months for repeated courses (blood tests). Success means a lasting drop in insomnia severity, higher sleep efficiency and better daytime function without next-day grogginess; absence of change after two courses suggests non-response. Any chest pain, neurological symptoms or injection-site infection ends use and prompts medical review.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ISI score 0–7 Primary insomnia outcome ISI: Insomnia Severity Index, a 7-item questionnaire; 8–14 subthreshold, ≥15 clinical insomnia; baseline, week 1, week 2
Sleep efficiency ≥90% Main outcome in DSIP trials Time asleep divided by time in bed; conventional threshold ≥85%; diary or wearable, average over 7 nights
Sleep onset latency 10–20 min Tracks faster sleep onset Conventional cut-off <30 min; <5 min may indicate sleep deprivation
Deep (slow-wave) sleep No established target; track change from own baseline DSIP’s proposed target Typically 13–23% of sleep in adults and falls with age; consumer wearables estimate it imprecisely
AHI <5 events/hour Excludes sleep apnea before use AHI: apnea–hypopnea index; conventional 5–14 mild, ≥15 moderate-to-severe; home sleep test at baseline if STOP-BANG ≥3
Fasting glucose 75–90 mg/dL Claimed glucose effects Conventional reference 70–99 mg/dL; 8–12 hour fast; pair with glycated hemoglobin
HbA1c 4.8–5.4% Three-month glucose average HbA1c: glycated hemoglobin; conventional normal <5.7%; baseline and every 3–6 months
Morning cortisol 10–18 µg/dL Claimed stress-hormone effects Conventional 5–23 µg/dL; draw 7–9 a.m.; human DSIP studies showed no effect
ALT <25 U/L Liver safety of unregulated injectable ALT: alanine aminotransferase, a liver enzyme; conventional upper limit about 40–55 U/L; part of CMP (comprehensive metabolic panel)
eGFR >90 mL/min/1.73 m² Kidney function baseline eGFR: estimated glomerular filtration rate, from creatinine; conventional normal >60; part of CMP

Qualitative markers:

  • Subjective sleep quality and feeling rested on waking
  • Morning grogginess or unintended daytime sleepiness
  • Daytime alertness, concentration and mood
  • Headache frequency after doses
  • Injection-site redness, swelling or pain

Emerging Research

  • No registered trials: A ClinicalTrials.gov search on 2026-09-30 for DSIP, delta sleep-inducing peptide, emideltide and Deltaran found no registered trials; no NCT ID (ClinicalTrials.gov registry number) exists. The absence leaves healthy-aging users without modern human safety or efficacy data.
  • US regulatory decision: FDA must still decide whether to act on its committee’s 6–7 vote against compounding emideltide; FDA staff cited missing safety and efficacy data (Eglovitch, 2026). A final rule would shape legal access.
  • Brain-penetrant fusion peptides: A DSIP fusion peptide engineered to cross the blood–brain barrier outperformed native DSIP in restoring sleep and neurotransmitter balance in insomnia-model mice (Mu et al., 2024), a direction that could strengthen the sleep case.
  • Ischemia analogues: The DSIP-like peptide KND reduced heart and brain infarct size when given during reperfusion (restored blood flow), but DSIP given during blockage was lethal in rats (Tukhovskaya et al., 2021), findings that cut both ways.
  • Endogenous origin: A sequence nearly identical to DSIP was found in JMJD1B histone demethylases (enzymes that remove chemical tags from DNA-packaging proteins), proposed as natural precursors (Mikhaleva et al., 2011); confirmation would strengthen the physiological rationale.
  • Insomnia replication: The independent negative trials (Bes et al., 1992; Monti et al., 1987) remain the latest controlled human sleep data; a modern polysomnography (overnight laboratory sleep recording) trial of subcutaneous dosing could confirm or overturn the Basel findings.
  • Longevity replication: The mouse lifespan and tumor findings (Popovich et al., 2003) come from one strain and one network; independent multi-site testing could strengthen or weaken the longevity claim.

Conclusion

DSIP is a small brain-active peptide discovered as a possible natural sleep signal and now sold as an injectable research product for sleep, stress resilience and healthy aging. For health-focused adults willing to self-inject, the evidence is thin and old. Early work from its discoverers reported normalized sleep, sharper daytime function and pain relief, and a separate group reported relief of withdrawal, but independent, carefully controlled sleep studies found only small changes of little practical importance, and the peptide did not change the stress hormone cortisol or growth hormone in healthy people. The longevity case rests entirely on animal studies: longer maximum lifespan, fewer tumors and antioxidant effects in rodents, all from one research network.

Reported side effects were mild, mainly headache and unwanted daytime sleepiness, but the people studied numbered only a few hundred, over weeks rather than years. The larger practical risks today come from unregulated manufacturing, sterile-injection technique, combining it with other sleep-promoting drugs, and an animal signal of harm during acute heart blockage. Much of the favorable human evidence came from the team that discovered the peptide and from a withdrawal group whose senior researcher co-held a drug-company patent, while the animal longevity work comes from the laboratories that developed a commercial preparation.

Overall, DSIP remains an intriguing but unresolved molecule whose promised benefits for sleep and aging are unconfirmed in people.

Top - Benefits - Risks - Protocol